arrow
L

Lori Muffly

stanford university school of medicine
H指数:34
被引数:5,529

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Consensus Recommendations for CAR T Cell Administration in Adult Acute Lymphoblastic Leukemia: A Modified Delphi Study

成人急性淋巴细胞白血病CAR T细胞输注的共识建议:一项改良德尔菲研究

Blood
IF23.1
2026-05-220
PRE
Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy

复发/难治性多发性骨髓瘤患者接受BCMA靶向CAR-T治疗后BCMA表达动力学

2026-04-040
OA
Allogeneic hematopoietic cell transplantation in acute myeloid leukemia not in complete remission: outcomes and prognostic factors in a contemporary cohort

异基因造血细胞移植在未达完全缓解的急性髓系白血病中的应用:当代队列的结局与预后因素

2025-11-250
OAAI
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia

CAR HEMATOTOX 独立预测急性淋巴细胞白血病接受CD19 CAR-T疗法后的结局

2025-10-080
OAAI
Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies

CD22 CAR T细胞在B-ALL中的治疗效果:两种制造策略的故事

2025-10-020
PRE
Hematopoietic Cell Transplantation, Version 3.2025

造血细胞移植,版本 3.2025

2025-10-011
PRE
The Impact of Anti-CD38 Monoclonal Antibody Therapy on Stem-Cell Mobilization Yields in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Referred from Community and Academic Oncology Practices: Single Center, Real World Data 2021-2024

抗CD38单克隆抗体疗法对来自社区和学术肿瘤学实践的新诊断多发性骨髓瘤(NDMM)患者干细胞动员产量的影响:单中心、真实世界数据2021-2024

2025-08-270
PRE
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia

社会决定因素对成人复发/难治性B细胞急性淋巴细胞白血病患者brexucabtagene autoleucel治疗结局的影响

2025-08-230
OAAI
Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia

移植预处理、NPM1突变及FLT3-ITD急性髓系白血病中可测量的微小残留病的影响

2025-07-030
OAAI
Fatal recurrence of IEC-HS after autologous stem cell boost in patients receiving BCMA-CAR T-cell therapy

自体干细胞加强治疗后BCMA-CAR T细胞治疗患者的IEC-HS致命复发

2025-05-140
OA